ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinomaJoyce Liu, Amit M Oza, Nicoletta Colombo, Ana Oaknin
29 October 2021
A phase III randomized clinical trial comparing sentinel node biopsy with no retroperitoneal node dissection in apparent early-stage endometrial cancer – ENDO-3: ANZGOG trial 1911/2020Andreas Obermair, Jim Nicklin, Val Gebski, Sandra C Hayes, Nicholas Graves, Linda Mileshkin, Ming Yin Lin, Phillip Beale, Eva Baxter, Kristy Robledo, Carlos Salomon, George B Hanna, Monika Janda
2 November 2021
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancerBradley J Monk, Robert L Coleman, Keiichi Fujiwara, Michelle K Wilson, Amit M Oza, Ana Oaknin, David M O’Malley, Domenica Lorusso, Shannon N Westin, Tamar Safra, Thomas J Herzog, Frederik Marmé, Ramez N Eskander, Kevin K Lin, Danny ShihSee the full list of authors
30 September 2021
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)Susana Banerjee, James Stewart, Nuria Porta, Christy Toms, Alexandra Leary, Stephanie Lheureux, Saira Khalique, Jeremy Tai, Ayoma Attygalle, Katherine Vroobel, Christopher J Lord, Rachael Natrajan, Judith Bliss
13 September 2021
BIOPSAR study: ultrasound-guided pre-operative biopsy to assess histology of sarcoma-suspicious uterine tumors: a new study protocolStamatios Petousis, Sabrina Croce, Michel Kind, Chrysoula Margioula-Siarkou, Guillame Babin, Caroline Lalet, Dennis Querleu, Anne Floquet, Marina Pulido, Frederic Guyon
29 September 2021
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)Lucia Musacchio, Vanda Salutari, Sandro Pignata, Elena Braicu, David Cibula, Nicoletta Colombo, Jean Sebastien Frenel, Flora Zagouri, Vittoria Carbone, Viola Ghizzoni, Serena Giolitto, Elena Giudice, Maria Teresa Perri, Caterina Ricci, Giovanni ScambiaSee the full list of authors
4 October 2021
Determining post-operative morbidity and mortality following gynecological oncology surgery: protocol for a multicenter, international, prospective cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative—GO SOAR)Faiza Gaba, Nicolò Bizzarri, Paul Kamfwa, Allison Saiz, Oleg Blyuss, Shantini Paranjothy, Pedro T Ramirez, David Cibula, , on behalf of the GO SOAR Team, Mohamedraed Elshami, Mahmoud Saad, Ahmed Nafea, Muhammed Elhadi, Alaa IsmailSee the full list of authors
6 September 2021
Neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel: a phase II, open label multicenter study (NUVOLA trial)Claudia Marchetti, Riccardo Tudisco, Vanda Salutari, Antonella Pietragalla, Giovanni Scambia, Anna Fagotti
15 June 2021
Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6)Günter Emons, Jae-Weon Kim, Karin Weide, Nikolaus de Gregorio, Pauline Wimberger, Fabian Trillsch, Boris Gabriel, Dominik Denschlag, Stefan Kommoss, Mustafa Aydogdu, Thomas Papathemelis, Martina Gropp-Meier, Mustafa-Zelal Muallem, Cristin Kühn, Andreas MüllerSee the full list of authors
5 July 2021
TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation programEric Lambaudie, Cécile Bannier/Braticevic, Charlène Villaron/Goetgheluck, Christophe Zemmour, Jean-Marie Boher, Patrick Ben Soussan, Jihane Pakradouni, Clement Brun, Leonor Lopez Almeida, Patricia Marino
1 December 2020